{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83"},{"groupId":"OG001","value":"31"}]}],"title":"SAEs"},{"categories":[{"measurements":[{"groupId":"OG000","value":"386"},{"groupId":"OG001","value":"178"}]}],"title":"Other Non-Serious AEs"}],"denoms":[{"counts":[{"groupId":"OG000","value":"438"},{"groupId":"OG001","value":"218"}],"units":"Participants"}],"description":"Clinically significant events were defined as serious adverse events (SAEs) and other non-serious AEs regardless of causality. A summary of serious and other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module.","groups":[{"description":"Pemetrexed: 500 mg/m\\^2, IV administration, q 21 days, until disease progression.\n\nBSC: Treatment without a specific antineoplastic regimen, given with the intent to maximize quality of life, as judged by the treating physician.","id":"OG000","title":"Pemetrexed and BSC"},{"description":"Placebo: IV administration, q 21 days.\n\nBSC: Treatment without a specific antineoplastic regimen, given with the intent to maximize quality of life, as judged by the treating physician.","id":"OG001","title":"Placebo and BSC"}],"paramType":"NUMBER","populationDescription":"Participants who signed the ICF, completed the randomized process and received at least 1 dose of study drug are reported according to the treatment to which they were received.","reportingStatus":"POSTED","timeFrame":"Baseline to study completion (up to 41 Months)","title":"Number of Participants With Adverse Events (AEs)","type":"SECONDARY","unitOfMeasure":"participants"}